Top Stocks For 2015: 11/9/14

Saturday, November 15, 2014

5 Best Biotech Stocks To Invest In 2014

Popular Posts: Hottest Technology Stocks Now – ASX DDD HIMX CDNS7 Biotechnology Stocks to Buy NowHottest Healthcare Stocks Now – CLVS CYH AZN MNKD Recent Posts: Hottest Healthcare Stocks Now – PRXL ALXN ACHC HMSY Biggest Movers in Financial Stocks Now – HOMB GBL RATE HTH Biggest Movers in Technology Stocks Now – WBMD ATHN ULTI ZNGA View All Posts

The commercial banking, aerospace and defense, biotechnology, auto parts and life science sectors are showing strength this week, according to Portfolio Grader.

Best Insurance Companies For 2015: Receptos Inc (RCPT)

Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.

As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.

As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.

Advisors' Opinion:

[By John Udovich]
Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
[By Ben Levisohn]
Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:
[By Roberto Pedone]
Receptos (RCPT) is a biopharmaceutical company engaged in discovering, developing and commercializing therapeutics for immune disorders. This stock closed up 5% at $23.19 in Monday's trading session.

Monday's Volume: 69,000

Three-Month Average Volume: 55,356

Volume % Change: 50%

From a technical perspective, RCPT ripped higher here right above some key near-term support at $21 with decent upside volume. This move is quickly pushing shares of RCPT within range of triggering a major breakout trade. That trade will hit if RCPT manages to take out its all-time high at $25 with high volume.

Traders should now look for long-biased trades in RCPT as long as it's trending above support at $21 and then once it sustains a move or close above its all-time high at $25 with volume that's near or above 55,356 shares. If that breakout hits soon, then RCPT will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $30 to $35.

5 Best Biotech Stocks To Invest In 2014: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.

Advisors' Opinion:

[By Keith Speights]
Another issue is fear over potential rivals. Gilead Sciences (NASDAQ: GILD ) , for example, reported in May that its�idelalisib produced significant tumor shrinkage in half of the patients involved in an early-stage trial. Dr.�Sandra Swain, president of the American Society of Clinical Oncology, called the results "pretty incredible." Gilead is also testing�idelalisib in the treatment of�non-Hodgkin's lymphoma.
[By John Udovich]
The latest biotech news or news surrounding small cap biotech stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX), Dendreon Corporation (NASDAQ: DNDN) and TNI BioTech, Inc (OTCMKTS: TNIB) includes a merger, a CEO resignation and a steady stream of IPO filings:
Merck Buys Idenix Pharmaceuticals. On Monday, Merck & Co, Inc (NYSE: MRK) and Idenix Pharmaceuticals announced that the companies had entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash in a deal worth approximately $3.85B. The deal is being seen as a way for Merck bolster its arsenal of potential drugs in the competitive arena of hepatitis C treatments��a space where Gilead Sciences, Inc (NASDAQ: GILD) is seen as a race leader�with Idenix Pharmaceuticals being a laggard. It should be noted that winning the race is important given that at least�3 million Americans and 150 million people worldwide have hepatitis C. The Captain Abandons the Dendreon Corporation Ship. On Monday, Dendreon Corporation, the financially troubled seller of the Provenge prostate cancer vaccine,�announced that John H. Johnson (who was hired to turn things around)�had informed the Board of Directors of his plans to step down as president and CEO for ��ersonal reasons.��That�� not a good omen because as Adam Feuerstein noted in TheStreet, Dendreon Corporation�must repay $28 million in debt by June 15.�That will not be a�problem but with just $170 million in the bank at the end of the first quarter, Dendreon Corporation has no means right now to repay the $560 million in debt due in 2016. However and as Mad Money�� Jim Cramer has observed, the Idenix Pharmaceuticals deal gives some hope that a buyout could save shareholders. Shortage of R&D at Big Pharma Creates Demand for Small Cap Biotechs. Joseph Pantginis, Ph.D., a biotech analysts with ROTH Capital Partners, was recently interviewed by The Life Sciences Report where he commented:
One thing that
[By John Udovich]
Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

5 Best Biotech Stocks To Invest In 2014: Taro Pharmaceutical Industries Ltd (TARO)

Taro Pharmaceutical Industries Ltd., incorporated in 1959, is a science-based pharmaceutical company. The Company develops manufactures, and markets prescription and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. The Company also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company�� primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through three companies: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries (including indirect), Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets more than 180 pharmaceutical products in over 25 countries.

Taro Israel manufactures more than 160 finished dosage form pharmaceutical products for sale in Israel and for export. It produces APIs used in the manufacture of finished dosage form pharmaceutical products. It markets and distributes generic products in the local Israeli market. Taro Israel�� primary product lines include dermatology, prescription and OTC semi-solid products (creams, ointments and gels) and liquids; cardiology and neurology, prescription oral dosage products; oral analgesics, both prescription and OTC, and OTC oral and nasal sprays and ophthalmic products.

Taro Canada manufactures more than 70 finished dosage form pharmaceutical products for sale in Canada and for export. It markets and distributes generic products in the local Canadian market. Its product line includes dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology, oncology, gastrointestinal and neurology: prescription oral and injects able dosage products, and allergy (antihistamine): OTC oral dosage products.

Taro U.S.A markets! and distributes generic products in the United States market. Its primary product lines include dermatology: prescription and OTC semi-solid products (creams, ointments and gels) and liquids, cardiology and neurology: prescription oral dosage products, and other prescription and OTC products.

The Company competes with Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer/Wyeth, Valeant, Galderma, Merck/Schering-Plough, Teva Pharmaceuticals U.S.A., Mylan Laboratories, Perrigo Company, Ranbaxy Pharmaceuticals Inc., Sandoz Pharmaceuticals, Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Schering-Plough Canada, Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Bayer Inc., Bristol-Myers Squibb Canada, Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated, Pharmascience Inc., Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexxon Ltd., Rafa Laboratories Ltd., Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc.

Advisors' Opinion:

[By Rich Smith]
Israeli drugmaker Taro Pharmaceutical Industries (NYSE: TARO ) has a new CEO -- and a new Chairman of the Board, as well.

On Thursday, Taro announced the imminent retirement of Interim Chief Executive Officer Mr. James Kedrowsk, who will be replaced August 1 by new permanent CEO Mr. Kalyanasundaram Subramanian ("Kal Sundaram"). Additionally, the company said that Dilip Shanghvi�has been appointed Chairman of its Board of Directors.
[By Ben Levisohn]
Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.

5 Best Biotech Stocks To Invest In 2014: Insys Therapeutics Inc (INSY)

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company�� pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company�� product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).

Subsys

The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.

Dronabinol Product Family

The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.

Cancer Therapeutics

In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.

The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Advisors' Opinion:

[By Jake L'Ecuyer]
Equities Trading DOWN
Shares of INSYS Therapeutics (NASDAQ: INSY) were down 15.94 percent to $38.00 after the company received subpoena from Office of Inspector General.
[By David Zeiler]
2. Insys Therapeutics Inc. (Nasdaq: INSY): Insys is a biotech seeking to capitalize on the growing interest in medical marijuana by using a generic form of THC to create drugs to treat cancer pain. INSY had its IPO May 2 with an offer price of $8 a share. The stock rose 19.75% on its first day of trading. But investors really warmed up to Insys later; it currently trades at about $37.54, a 369.25% increase over the offer price.
[By Louis Navellier]
INSYS Therapeutics (INSY) is a biotech company that focuses on developing pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Their products include drugs that help patients deal with pain form the disease and help alleviate nausea and pain from chemotherapy. The company reported earnings this week and both profits and sales have exploded higher.

Friday, November 14, 2014

Hot Medical Stocks To Watch For 2014

LONDON -- For a country that is said to have lost its industrial base, there are plenty of flourishing engineering companies in the FTSE 100, such as 拢5.2 billion�Smiths Group� (LSE: SMIN ) . This is more than an engineer, it's a global technology business whose five divisions cover everything from contraband detection to medical devices, energy and communications. Should I buy it?

Smiths Group has just published a market-pleasing interim management statement, showing rising underlying revenue across all five of its divisions in the nine months to May 4. Underlying headline operating profit also rose, as did headline operating margin, with the exception of Smiths Medical, where profits have been knocked by a new U.S. medical device tax, and substantial investment in sales and marketing.

Cautious investment
Investor enthusiasm has been tempered by recent management caution, which has been warning of tough trading conditions to come, and loss of revenues due to government spending cuts. Yet the share price has had a solid 12 months, rising 32% against 24% for the FTSE 100 as a whole. Over three years it has slightly underperformed, rising 28% against 32% for the index. Investors can't complain, but they won't be breaking out the bubbly either.

10 Best Restaurant Stocks To Buy For 2015: Oramed Pharmaceuticals Inc (ORMP)

Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.

The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.

Advisors' Opinion:

[By Ben Levisohn]
Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.

BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.
[By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.
[By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.

Hot Medical Stocks To Watch For 2014: Bio-Reference Laboratories Inc.(BRLI)

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

Advisors' Opinion:

[By Ben Levisohn]
As a result, LabCorp has dropped 11% to $87.79 and has helped drag down competitors like Quest Diagnostics (DGX), and BioReference Laboratories (BRLI).
[By GuruFocus]
An example here is Bio Reference Lab (BRLI). This is a company with a simple business, strong balance sheet and the Predictability Rank of 5-Star. At the price of $19, BRLI was in the top of the Buffett-Munger Screener. But the stock price quickly dropped to below $12 in November 2011. At that point, the company announced a share buyback. The CEO, CFO and COO also bought shares in December at $14 a share. Since then the stock price has doubled.
[By Geoff Gannon] strong>DreamWorks (DWA)
Read these reports. Look for something that might have interested me. Why would Geoff look at DNB, Chuck E. Cheese, etc.? What got him interested in the stock? Do I see the same thing?
Whenever possible, also read the quarterly earnings call transcripts. You can listen to them too. But it�� easier if you read them and listen to them.
Just listening is a bad idea.
Whenever I can get a transcript of anything ��even Warren Buffett�� appearance on CNBC ��I��l keep a copy of the transcript even when I have a copy of the video (or audio). You can refer back to a transcript easily. You can highlight. You can take notes.
Taking Notes
Now, you are doing those things when reading an annual report, right?
You never just sit down and read an annual report. You always sit down with a pen, a highlighter, a pad of paper, and a calculator. Use the margins of a 10-K ��or your pad of paper ��to jot down notes. Ask questions. Do calculations.
If you ever see a 10-K after I��e read it ��it�� not very white anymore. There�� lots of stuff written in the margins. Mostly it�� questions I was asking myself. But it�� also calculations of numbers the company does not provide.
Numbers to Know
So, for example, in a bank�� 10-K I always write down:
路 Deposits per share
路 Deposits per branch
路 Cost of deposits
路 Texas Ratio
You can actually look up the Texas Ratio of any bank here. And some banks calculate and report cost of deposits the way I like to think about it. But, it�� not common for banks to report deposits per branch ��although small banks will sometimes mention (perhaps in the shareholder letter) what their biggest branch has in deposits. Others may mention how quickly new branches achieved a deposit milestone.
Those are the kinds of numbers I write in the margins of a bank�� 10-K. There will be questions like: ��hy is e
[By Geoff Gannon]
But if you can definitely hold a company through a tough market that lasts a few years ��then you can look for a wonderful business to buy and hold at any time. In any market. I found some lovely businesses around the time of the 2000 market peak. They just weren�� big caps, dot coms, etc. They were smaller more mundane businesses. In at least one case ��Bio-Reference Labs (BRLI) ��I made some money (it seemed like a scary big amount at the time) holding the stock for about 2 years but I would��e made a whole lot more if I had just held that one stock through till today. And even now BRLI seems a fine stock to keep holding. So, you see I could��e saved myself a lot of trouble by holding something for more than 10 years. And it wouldn�� have hurt my performance at all. In fact, BRLI has beaten the market by a lot for a very long time. And, yes, the price I paid for BRLI happens to be the most I ever paid for a stock relative to its record earnings. So, I paid a very high price ��for a value investor like me ��for a stock that promptly went on to return around 20% a year for the next 10 years and is now back at almost the exact same P/E ratio where I first bought it.

Hot Medical Stocks To Watch For 2014: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

[By John Udovich]
On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what�� driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
[By Sean Williams]
What: Shares of Clovis Oncology (NASDAQ: CLVS ) , a biopharmaceutical company that's developing anti-cancer therapies, vaulted higher by as much as 136% (that's not a typo!) after reporting positive data on two early stage experimental treatments -- CO-1686 in EGFR-mutant non-small cell lung cancer (NSCLC) and Rucaparib in a monotherapy study of solid tumors -- at the American Society of Clinical Oncology's annual meeting.

Hot Medical Stocks To Watch For 2014: Decision Diagnostics Corp (DECN)

Decision Diagnostics Corp., formerly instaCare Corp., incorporated on March 2, 2001, is a prescription and non-prescription diagnostics and home testing products distributor. The Company distributes brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound cares and post-surgery medical products. The Company through its subsidiaries, PDA Services, Inc. and Decision IT Corp. offers information technology solutions in several medical cares market channels by providing physicians with information at the point of care. The Company's retail prescription business maintains three operating units, which include Licensed wholesale prescription drug distribution business; Licensed distribution of diabetes diagnostics and supplies; and Internet pharmacy/prescription fulfillment.

The Company's software is designed to integrate point of service applications. The Company is also a developer of products that offer solutions in medical care and management by providing physicians with essential information instantaneously as they meet with their patients. In addition, the Company markets its MD@Hand and MD @Work software application, which also leverages the connectivity of smart cell phones devices through the Internet. The Company's applications run on smart phones manufactured by Apple, Palm, Motorola and Samsung.

Advisors' Opinion:

[By Bryan Murphy]
Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).

Hot Medical Stocks To Watch For 2014: Amarantus Bioscience Holdings Inc (AMBS)

Amarantus BioScience Holdings, Inc., formerly Amarantus BioSciences, Inc., incorporated on March 22, 2013, is focuses on developing intellectual property and proprietary technology in order to develop drug candidates and diagnostic blood tests to diagnose and treat human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), owns the intellectual property rights to biomarkers related to oncology and neurodegeneration named BC-SeraPro and NuroPro respectively, has a license to an Alzheimer�� disease blood test named LymPro, and owns a number of proprietary cell lines called PhenoGuard. MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. In December 2012, the Company acquired neurodegenerative diagnostic portfolio from Power3 Medical Products. On March 22, 2013, the Company was merged with into Amarantus Bioscience Inc.

The Company also owns an inventory of 88 cell lines that Amarantus refers to as PhenoGuard Cell Lines. MANF is a protein that corrects protein misfolding. The Company�� MANF product development effort is centered on a therapy for Parkinson�� disease.

Advisors' Opinion:

[By Bryan Murphy]
I've taken bullish swings on - and been wrong to do so - Amarantus BioScience, Inc. (OTC:AMBS) before. My most recent bullish call on the budding biotech name was in April... a rally that fizzled shortly after I said it was just getting started. Somehow though, I find myself coming back to AMBS as a breakout candidate. This time, however, it's for a slightly different reason.
[By James E. Brumley]
Judging from the company it's keeping Green Automotive Co. (OTCMKTS:GACR) may have just made its way into the upper echelon of small cap stock opportunities. The electric car company joins Elite Pharmaceuticals Inc. (OTCBB:ELTP), Amarantus Bioscience Holdings, Inc. (OTCBB:AMBS), and only three other companies as Wall-Street.com's "Best 6 Stocks" for January of 2014. As one of the top information resources for investors - particularly in terms of information regarding small and micro cap stocks - being named among the site's top pick is an accolade for AMBS, ELTP, and GACR. Even more impressive is that Green Automotive Co. was the only consumer-goods name among those six. Amarantus Bioscience Holdings and Elite Pharmaceuticals are biotechnology names... an industry that can and often does attract a lot of attention just by the nature of the business. The other three names making the "Best 6" list were an energy explorer, a power-management technology manufacturer, and prescription/medical food producer. For an electric car manufacturer to make the list speaks quite highly of GACR.
[By James E. Brumley]
What do Acasti Pharma Inc. (NASDAQ:ACST), Kandi Technologies Group Inc. (NASDAQ:KNDI), and Amarantus Bioscience Holdings, Inc. (OTCBB:AMBS) have in common? Not a lot, if you're simply looking at their business lines. Kandi Technologies Group makes electric cars, and even though Amarantus Bioscience Holdings and Acasti Pharma are both in the pharmaceutical arena, they're not too much alike. There is one common element among AMBS, ACST, and KNDI right now, however... they're three of the market's most bullish setups. Anyone looking for a new trading idea here should start with one of these three.

Hot Medical Stocks To Watch For 2014: Atrion Corp (ATRI)

Atrion Corporation (Atrion), and its subsidiaries, develop and manufacture products, primarily for medical applications. The Company�� medical products range from fluid delivery devices to ophthalmic and cardiovascular products. During the year ended December 31, 2011, the Company�� fluid delivery products accounted for 38% of the Company�� revenues. These products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications, including anesthesia and oncology.

The Company�� cardiovascular products accounted for 29% of its revenues during 2011. The Company's principal cardiovascular product is the Myocardial Protection System (MPS2), a technology that delivers essential fluids and medications to the heart during open-heart surgery. The MPS2 integrates key functions relating to the delivery of solutions to the heart, such as varying the rate and ratio of oxygenated blood, crystalloid, potassium and other additives, and controlling temperature, pressure and other variables to allow simpler, more flexible management of this process, indicating improved patient outcomes. The MPS2 is the device used in open-heart surgery that allows for the mixing of drugs into the bloodstream without diluting the blood. The MPS2 employs advanced pump, temperature control and microprocessor technologies and includes a line of disposable products. It also develops and manufactures other cardiovascular products that include cardiac surgery vacuum relief valves; Retract-O-Tape silicone vessel loops for retracting and occluding vessels in minimally inva! sive surgical procedures; inflation devices for balloon catheter dilation, stent deployment and fluid dispensing, and Clean-Cut rotating aortic punch and PerfectCut Aortotomy System, both of which are used in heart bypass surgery to make a precision opening in the heart for attachment of the bypass vessels.

The Company�� ophthalmic products accounted for 17% of its revenues during 2011. The Company is a manufacturer of contact lens disinfection cases. It also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. The Company�� other medical and non-medical products accounted for 16% of its revenues during 2011. These product lines consist of instrumentation and associated disposables used to measure the activated clotting time of blood. In addition, it manufactures and sells a line of products designed for safe needle and scalpel blade containment. It is also the manufacturer of inflation systems and valves used in marine and aviation safety products. The Company manufactures inflation systems and valves for products, such as life vests, life rafts, inflatable boats, survival equipment and other inflatable structures. The Company also produces one-way and two-way pressure relief valves for use on electronics cases, munitions cases, pressure vessels, transportation container cases, escape slides, and many other medical and non-medical applications.

The Company market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It sells its products through a sales force which consists of direct sales personnel, independent sales representatives and distributors. It offers customer service, training and education, and technical support such as field service, spare parts, maintenance and repair for certain of its products. The Company�� medical products and other components are produced at facilities in ! Florida, ! Alabama and Texas.

Advisors' Opinion:

[By Seth Jayson]
There's no foolproof way to know the future for ATRION (Nasdaq: ATRI ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.

Thursday, November 13, 2014

Hot Wireless Telecom Companies To Own For 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Illumina (NASDAQ: ILMN ) , a life science diagnostics company, rallied as much as 15% after the company reported better-than-expected first-quarter earnings results.

So what: For the quarter, Illumina reported a 21% boost in revenues to $331 million with an adjusted profit of $0.46 per share. Wall Street had only expected Illumina to post a profit of $0.39 on just $310.7 million in sales. If there were one blemish to the quarter, it was that the company took a $106.9 million charge related to ongoing patent litigation with Syntrix Biosystems.

Now what: Having witnessed Thermo Fisher Scientific�scoop up Life Technologies�last week, the sector is still abuzz with optimism. While I don't think Illumina is going to be receiving any takeover bids, I'm very intrigued by the outlook for life science diagnostics companies in general with regard to helping personalize cancer care over the remainder of the decade. Illumina appears to be a bit pricey here, but it's certainly a name worth considering for the future.

Top 10 Dividend Companies To Invest In Right Now: TechnoConcepts Inc (TCPS)

TechnoConcepts, Inc. (TCI), incorporated in May 2003, is in the business of designing, developing, manufacturing and marketing wireless communications semiconductors. The Company has begun manufacturing wireless transmitter and receiver microchips, based on its technology, and produced its engineering run in August 2006. The technology, which TCI calls True Software Radio, is designed to improve the way that wireless signals are received and transmitted, by making possible device-to-device communication across otherwise incompatible networks and wireless standards. On October 17, 2005, the Company, through its wholly owned subsidiary, Asante Acquisition Corp. completed reorganization with RegalTech Inc. RegalTech's name was changed to Asante Networks Inc. (Asante).

In December 2005, the Company formed Jinshilin Techno Ltd. (Jinshilin Techno) as its wholly owned subsidiary based in Shanghai, China. The Company organized Jinshilin Techno to provide marketing, sales and technical support for True Software Radio technology in China. On April 21, 2006, Jinshilin Techno acquired Internet television (IPTV) set-top box (STB) technology through license agreements with Jinshilin Technologies Development Company Ltd. (Jinshilin). Jinshilin Techno offers an IPTV set-top box that features voice over Internet protocol (VOIP), capability and can receive Internet protocol (IP) data transmissions through the household electrical power grid.

Asante Networks Inc. provides Ethernet networking solutions for Apple Computer and the small-to-medium business retail markets, offering the IntraCore and FriendlyNET product families, integrating voice, data, and video over wireless and wired networks with unified management and authentication. In April 2006, Asante announced the release of 2-chip switch solution, the IntraCore 38480. The IntraCore 38480 provides no frame loss and full-wire speed with minimized latency. With 96-gigabit switching fabric, the IntraCore 38480 supports full-wire speed on all ! ports. It has advanced traffic control based on L2-L7 data of incoming frames.

The Company's True Software Radio technology makes possible for wireless transmitters and receivers, as well as the radio signal processing, to be fully controlled and reconfigured by software commands across a range of frequencies and frequency bands. Its True Software Radio technology is a delta-sigma microchip architecture that converts radio frequency signals directly into digital data for the wireless receiver and directly from digital data into radio signals for the wireless transmitter. True Software Radio microchips replace the analog front end, intermediate frequency (I/F) processing, analog-to-digital conversion (ADC), and digital filtering sections of conventional wireless transmitters and receivers.

Advisors' Opinion:

[By Peter Graham]
Small cap tech stocks TechnoConcepts, Inc (OTCMKTS: TCPS), Unisource Corporation (OTCMKTS: USRC) and Strategic Global Investments, Inc (OTCMKTS: STBV) have been getting some attention lately in various investment newsletters thanks to promotions. Of course, there is nothing wrong with properly disclosed promotions, but they can backfire on the unwary as its really up to investors or traders alike to do their own due diligence before investing or trading. With that in mind, here is a quick reality check about three small cap tech stocks getting a bit of attention lately:
TechnoConcepts, Inc (OTCMKTS: TCPS) Has the Yield Sign Replaced on Its OTC Page
Small cap TechnoConcepts is a wireless technology company currently holding patents and other intellectual property. On Friday, TechnoConcepts fell 0.45% to $15.58 for a market cap of $415.28 million plus TCPC is up 1.1% over the past year and up 6% since April 2012 according to Google Finance.

Hot Wireless Telecom Companies To Own For 2014: CalAmp Corp (CAMP)

CalAmp Corp. (CalAmp) develops and markets wireless technology solutions that deliver data, voice and video for critical networked communications and other applications. The Company has two business segments: Wireless DataCom, which serves commercial, industrial and government customers, and Satellite, which focuses on the North American Direct Broadcast Satellite (DBS) market. In May 2012, CalAmp Corp announced that it has entered into a five-year supply agreement to provide fleet tracking products to Navman Wireless. As part of the transaction, CalAmp has acquired certain products and technologies from Navman Wireless and established a research and development center in Auckland, New Zealand. The assets acquired by CalAmp include technology for Mobile Display Terminals (MDT) and an MDT product line marketed to telematics original equipment manufacturers (OEMs) globally. In March 2013, it completed the acquisition of the operations of Wireless Matrix Corporation.

Wireless DataCom

The Wireless DataCom segment provides wireless technology, products and services for industrial Machine-to-Machine (M2M) and Mobile Resource Management (MRM) market segments for a range of applications, including optimizing and automating electricity distribution and ancillary utility functions; facilitating communication and coordination among emergency first-responders; increasing productivity and optimizing activities of mobile workforces; improving management control over valuable remote and mobile assets, and enabling emerging applications in a wirelessly connected world.

The Company's Wireless DataCom segment is comprised of a Wireless Networks business and an MRM business. CalAmp's Wireless Networks business provides products, systems and services to industrial, utility, energy and transportation enterprises and state and local governmental entities for deployment where the ability to communicate with mobile personnel or to command and control remote assets is crucial. Utilities! , oil and gas, mining, railroad and security companies rely on CalAmp products for wireless data communications to and from outlying locations, permitting real-time monitoring, activation and control of remote equipment. Applications include remotely measuring freshwater and wastewater flows, pipeline flow monitoring for oil and gas transport, automated utility meter reading, remote Internet access and perimeter monitoring. CalAmp is among the leaders in the application of wireless communications technology to Smart Grid power distribution automation for electric utilities.

MRM wireless solutions include global positioning system (GPS) location, cellular data modems and programmable events-based notification firmware as key components, allowing customers to know where and how their assets are performing, no matter where those mobile assets are located. Commercial organizations, vehicle finance providers, city and county governments, and a range of other enterprises rely on CalAmp products and systems to optimize delivery of services and protect valuable assets. Applications include fleet management, asset tracking, student and school bus tracking and route optimization, stolen vehicle recovery, remote asset security, remote vehicle start, and machine-to-machine communications. In addition to functioning as an OEM supplier of location and communications hardware for MRM applications, CalAmp is a total solutions provider of turn-key systems incorporating location and communications hardware, cellular airtime and Web-based remote asset management tools and interfaces.

The Company competes with Motorola Solutions, GE-MDS, Freewave, Sierra Wireless, GenX, Spireon, Novatel Wireless-Enfora and Xirgo.

Satellite

The Satellite segment develops, manufactures and sells DBS outdoor customer premise equipment and whole home video networking devices for digital and high definition satellite television (TV) reception. CalAmp's satellite products are sold primarily to ! EchoStar,! an affiliate of Dish Network.

The Company's DBS reception products are installed at subscriber premises to receive television programming signals transmitted from orbiting satellites. These DBS reception products consist principally of outdoor electronics that receive, process, amplify and switch satellite television signals for distribution over coaxial cable to multiple set-top boxes inside the home that can acquire, recognize and process the signal to create a picture.

The Company competes with Sharp, Wistron NeWeb Corporation, Microelectronics Technology, Pro Brand and Global Invacom.

Advisors' Opinion:

[By Rich Bieglmeier]
[Related -CalAmp (CAMP) To Supply Mobile Data Network For City Ff Buffalo Emergency Services]
CalAmp develops and markets wireless technology solutions that deliver data, voice and video for critical networked communications and other applications. The Company has two business segments: Wireless DataCom, which serves commercial, industrial and government customers, and Satellite, which focuses on the North American Direct Broadcast Satellite (DBS) market.
[By Sara Sjolin]
In the corporate sector, CalAmp Corp. (CAMP) �is likely to move. Shares dropped late Monday after its outlook for the current quarter fell short of Wall Street estimates.
[By Monica Gerson]
Shares of CalAmp (NASDAQ: CAMP) tumbled 7% on Tuesday after the company issued a downbeat outlook for the fourth quarter. Analysts at First Analysis also downgraded the stock from Overweight to Equal-Weight. CalAmp shares closed at $25.63 on Tuesday.

Hot Wireless Telecom Companies To Own For 2014: T-Mobile US Inc (TMUS)

T-Mobile US, Inc., formerly MetroPCS Communications, Inc., incorporated on March 10, 2004, is a wireless telecommunications carrier, which offers wireless broadband mobile services primarily in metropolitan areas in the United States, including the Atlanta, Boston, Dallas/Fort Worth, Detroit, Las Vegas, Los Angeles, Miami, New York, Orlando/Jacksonville, Philadelphia, Sacramento, San Francisco and Tampa/Sarasota metropolitan areas. Its flagship brands include T-Mobile and MetroPCS. As of December 31, 2012, it held licenses for wireless spectrum suitable for wireless broadband mobile services covering a total population of 144 million people in and around many of the metropolitan areas in the United States. It provides its services using code division multiple accesses (CDMA) networks using 1xRTT technology and evolution data optimized (EVDO) and fourth generation long term evolution (4G LTE).

The Company has roaming agreements with other wireless broadband mobile carriers that allow them to offer its customers service in many areas when they are outside its service area. These roaming agreements, together with the area it serve with its own networks, allows its customers to receive service in an area covering over 280 million in total population under the Metro USA brand. The Company sells products and services to customers through its Company-owned retail stores, as well as indirectly through relationships with independent retailers and third party dealers. Its service allows its customers to place unlimited local calls from within its local service area and to receive unlimited calls from any area while in its service area, for a flat-rate monthly service fee. For additional usage fees, it also provide certain other value-added services. All of these plans require payment in advance for one month of service. If no payment is made in advance for month of service, service is suspended at the end of the month that was paid for by the customer and, if the customer does not pay within 30 day! s, the customer is terminated. It believes its service plans differentiate them from the more complex plans and long-term contract requirements of traditional wireless carriers.

The Company voice services allow customers to place voice calls to, and receive calls from, any telephone in the world, including local, domestic long distance, and international calls. Its voice services also allow customers to receive and make calls while they are located in areas served by its networks and in those geographic areas served by the networks of certain other wireless broadband mobile carriers with whom it has roaming arrangements. The Company�� data services include text messaging services (domestic and international); multimedia messaging services; mobile Internet access; mobile instant messaging; location-based services; social networking services; push e-mail; multimedia streaming and downloads; and services provided, depending on the network and locale, through the Binary Runtime Environment for Wireless, or BREW, Blackberry, Windows, and the Android platforms, such as ringtones, ring back tones, games, content, and applications.

The Company�� Custom calling features offers custom calling features, including caller ID, call waiting, three-way calling and voicemail. Its Advanced handsets sells a variety of feature phones, and increasingly, smartphones, predominately manufactured by nationally recognized manufacturers for use on its network, including models that have cameras, include HTML browsers, play music, play streaming audio, display streaming video and downloaded video, and have other features facilitating digital data. It sells a variety of handsets using vendor or handset specific operating systems, such as BREW, Blackberry, Windows, and the Android operating system.

The Company provides its wireless broadband mobile services using paired personal communications services (PCS), spectrum and advanced wireless services, or AWS, spectrum. In addition, it holds a! license ! for 12 MHz of paired 700 MHz Lower Band A spectrum in the Boston-Worcester, MA/NH/RI/VT basic economic area (BEA), which, unless it receives a waiver from the Federal Communications Commission (FCC), of the four year construction requirements, it plans to construct in the first half of 2013. In each of its metropolitan areas where irt provides service. As of December 31, 2012, it holds between 10 mega hertz (MHz) and 60 MHz of paired spectrum and on average it has approximately 22 MHz of paired spectrum in the metropolitan areas it serves. In the aggregate, as of December 31, 2012, it offers wireless broadband mobile services using its own network.

The Company operates 1xRTT CDMA networks in all of the metropolitan areas it serves and it has upgraded its networks to 4G LTE in all of metropolitan areas. It also has deployed EVDO at selected high use sites in its CDMA network to increase network data capacity to meet the growing data needs of iy customers. Its network includes a mobile switching center (for CDMA), enhanced packet core (for 4G LTE), and IP core. These serve several purposes, including routing traffic, managing call handoffs, and managing access to the public switched telephone network (for CDMA) or the Internet (CDMA and 4G LTE). These network elements also provide access to voicemail and other value-added services, base stations (for CDMA) or eNodeBs (for 4G LTE), cell sites or distributed antenna system (DAS), nodes, and backhaul facilities, which carry traffic to and from its cell sites and its switching or enhanced packet core facilities, consisting of a combination of dedicated circuits, cable, fiber, and microwave facilities.

Its cell sites in the network are co-located, meaning its equipment is located on leased facilities that are owned by third parties who retain the right to lease the locations to additional carriers and in many cases other wireless broadband mobile service providers already have facilities at such locations. The switching centers and na! tional op! erations center provide around-the-clock monitoring of its network. Its switches connect to the public switched telephone network through fiber rings leased from third-parties, which transmit originating and terminating traffic between its equipment and local exchange and long distance carriers. It also has negotiated interconnection agreements with relevant local exchange carriers, or LECs, in its service areas. It uses third-party providers for domestic and international long distance services, international SMS interconnection with the public switched network and other carriers, roaming services, and the majority of its backhaul services.

The Company competes with AT&T, Verizon Wireless, Sprint Nextel, T-Mobile USA , Deutsche Telekom, Clearwire, Dish Network , Time Warner Cable, Comcast, Cox Communications, Cricket Communications, Leap Wireless International and Google.

Advisors' Opinion:

[By WALLSTCHEATSHEET]
T-Mobile is attempting to revolutionize the communications industry by providing less-restricted products and services to consumers and companies. Investors and consumers alike are both eagerly awaiting more details about the company’s Uncarrier Phase III. The stock has been surging higher since its IPO and is now trading at all time highs. Over the last four quarters, investors have had mixed feelings as earnings have been mixed while revenues have been rising. Relative to its peers and sector, T-Mobile has been a year-to-date performance leader. Look for T-Mobile to OUTPERFORM.
[By Evan Niu, CFA and Erin Kennedy]
Recently, T-Mobile (NYSE: TMUS ) has been shaking things up in the domestic wireless industry with its "Uncarrier" strategies. However, the company's latest move seems somewhat removed from this philosophy, and has caused some backlash among consumers. While T-Mobile has made pricing transparency a priority, CEO John Legere just announced that the company is getting rid of its corporate employer rate plan discounts. While this could make prices more transparent, it could also cause them to go up significantly for a large number of T-Mobile users.
[By Ravagadus]
The fourth largest telecom ��ncarrier��in United States, T-Mobile (TMUS) is looking to recreate some fond memories. Two years ago AT&T had tried to acquire T-Mobile, but failed and ended up paying a fortune as breakup fee.Now, Sprint too could be following its footsteps.

Hot Wireless Telecom Companies To Own For 2014: Tim Participacoes SA (TIMP3)

TIM Participacoes SA (TIM) is a Brazil-based holding company engaged in the telecommunications segment. Through its wholly-owned subsidiaries, TIM Celular SA (TIM Celular) and Intelig Telecomunicacoes Ltda (Intelig), it provides telecommunication services throughout Brazil. TIM Celular and Intelig are active as Public Switched Telephony Network (PSTN) providers in the local and national and international long-distance modalities in all Brazilian states. Additionally, the Company provides multimedia communication services and personal mobile services, mobile data services and a third generation (3G) network, as well as international roaming agreements, multimedia messaging services, blackberry services and sale of related equipment. Advisors' Opinion:

[By Zahra Hankir]
Brazil�� Ibovespa extended its weekly decline to 3.3 percent. Mobile carrier Tim Participacoes SA (TIMP3) sank after parent Telecom Italia SpA (TIT)�� chief executive officer said its Brazilian assets are strategic, damping speculation the local unit will be sold.
[By Jonathan Morgan]
Telecom Italia SpA (TIT) jumped 6.2 percent to 65.6 euro cents. The phone company that was stripped of its investment-grade rating is seeking at least 9 billion euros for its controlling stake in Brazilian wireless carrier Tim Participacoes SA (TIMP3), according to a person with direct knowledge of the matter.
[By Inyoung Hwang]
Telecom Italia climbed 5.2 percent to 64.2 euro cents, its highest price since May. The telecommunications operator would gain enough funds to improve its domestic business if it sells at least 4 billion euros ($5.4 billion) of shares or its stake in Tim Participacoes SA (TIMP3) in Brazil, according to Goldman Sachs.

Hot Wireless Telecom Companies To Own For 2014: Rewards Nexus Inc (ERNI)

Rewards Nexus Inc., formerly NIS Holdings Corp., incorporated on June 21, 2004, through its subsidiaries, operates in the loyalty/rewards industry. The Company has launched the Earn IQ rewards program, a consumer loyalty platform-coupled with marketing and advertising services for various industries.

The Company provides consumers with opportunities to interact and engage with online and mobile products. It primarily focuses on various business sectors, including the customer loyalty management market, the gift card industry, the online food ordering industry, and the marketing consulting industry

Advisors' Opinion:

[By Peter Graham]
Small cap stocks Rewards Nexus Inc (OTCMKTS: ERNI), MyEcheck Inc (OTCMKTS: MYEC) and ITonis Inc (OTCMKTS: ITNS) fell 29.6%, 18.92% and 9.09%, respectively, last Friday. Moreover, some of these small cap stocks are already making big moves again this morning - perhaps in part because they have all been the subject of recent paid promotions. So where are these small cap heading this week and for the long term? Here is a quick reality check:

Hot Wireless Telecom Companies To Own For 2014: Intelsat SA (I)

Intelsat S.A., incorporated on July 18, 2011, is a satellite services business, providing a layer in the global communications infrastructure. The Company operates satellite capacity, holds orbital location rights, contract backlog, serve commercial customers and deliver services. It provides diversified communications services to the world�� media companies, fixed and wireless telecommunications operators, data networking service providers for enterprise and mobile applications, multinational corporations and Internet service providers (ISPs). It is also the provider of commercial satellite capacity to the United States government and other select military organizations and their contractors.

The Company has a satellite fleet comprised of more than 50 satellites, covering 99% of the Earth�� populated regions. Its fleet, combined with the IntelsatOne terrestrial fiber network and a collection of teleports, form a singular unmatched global infrastructure to meet any communications requirement. As the provider of satellite services, the Company provides mission critical communication services.

Advisors' Opinion:

[By Rich Duprey]
Satellite services provider�Intelsat (NYSE: I ) announced yesterday its second-quarter dividend of $0.799 per share on its 5.75% Series A mandatory convertible junior non-voting preferred stock, which trades on the NYSE under the symbol I.PRA.
[By The Specialist]
Subject to ongoing evaluation and analysis, the Reporting Person may consider certain plans or proposals to increase shareholders' value that may relate to or may result in (I) a change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; and/or (ii) a material change in the present dividend policy of the Issuer

Top Telecom Companies To Watch For 2014

In the fast-paced, dog-eat-dog world of big tech, fortunes come and go quickly. One such example is the fallen star of French telecom equipment, Alcatel颅-Lucent (NYSE: ALU ) . The company's been through the wringer since its merger several years ago. With its shares having skyrocketed over the past several months, investors are hoping the company has finally regained its mojo after struggling through a harrowing turnaround process. However, it might not be that simple, as our tech and telecom analyst shows in the following video.

As many of us know, mobile could be a genuine opportunity for Alcatel-Lucent, because this revolution is still in its infancy in many ways, but with so many different companies it can be daunting to know how to profit in the space. Fortunately, The Motley Fool has released a free report on mobile named "The Next Trillion-Dollar Revolution" that tells you how. The report describes why this seismic shift will dwarf any other technology revolution seen before it and also names the company at the forefront of the trend. You can access this report today by clicking here -- it's free.

10 Best International Stocks To Own Right Now: Partner Communications Company Ltd.(PTNR)

Partner Communications Company Ltd. provides various telecommunications services in Israel. It offers cellular telephony services on GSM/GPRS and UMTS/HSDPA networks. The company also provides basic services, including domestic mobile calls, international dialing, roaming, voice mail, short message services, intelligent network services, content based on its cellular portal, data and fax transmission, and other services. In addition, it offers Internet services provider services that provides access to the Internet, as well as home WiFi networks; value added services, such as anti-virus and anti-spam filtering; and transmission services; and Web video on demand services, music tracks, and games. Further, the company provides voice over broadband and primary rate interface fixed-line telephone services; and data capacity services. Additionally, it offers content services comprising voice mail, text, and multimedia messaging, as well as downloadable wireless data application s, including ring tones, music, games, and other informational content; and sells handsets, phones, routers, and related equipment. The company markets its products through its sales centers, business sales representatives, traditional networks of specialized dealers, and non-traditional networks of retail chains and stores under the Orange brand name. Partner Communications Company Ltd. was founded in 1997 and is headquartered in Rosh Ha-ayin, Israel.

Advisors' Opinion:

[By Eddie Staley]
Telecommunications services shares jumped around 1.19 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), China Unicom (Hong Kong) (NYSE: CHU), and Partner Communications Company (NASDAQ: PTNR).
[By Garrett Cook]
Telecommunications services shares jumped around 1.19 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), China Unicom (Hong Kong) (NYSE: CHU), and Partner Communications Company (NASDAQ: PTNR).

Top Telecom Companies To Watch For 2014: Iliad SA (ILIAF.PK)

Iliad SA is a France-based holding company active in the integrated telecommunications sector. The Company provides Internet access services, hosting services and others. Iliad SA is also focused on fixed-line telephony services and the provision of wireless fidelity (WiFi) cards, among several others. In addition, Iliad SA sells via Internet a range of insurance policies. As of December 31, 2012, the Company had a number of subsidiaries, which include Free SAS, Centrapel SAS, Freebox SAS, Telecom Academy SARL, Free Frequences SAS, Iliad 1 SAS, Iliad 2 SAS, Protelco SAS, IFW SAS, IRE SAS, Management Centre De Relation Abonne (MCRA), F Distribution SAS, and Centrapel SAS, among others. Its Fixe subsidiary is a landline business-provider of broadband Internet services. As of year-end 2012, the Company was active as a operator in more than 35 countries. Advisors' Opinion:

[By Mike Arnold]
I normally don't look at charts much, but comparing Orange to its competitors in the French telecommunications market is quite fascinating. As one can see, incumbents Bouygues (BOUYF.PK) and Vivendi (VIVHY.PK) (owner of SFR) saw similar price declines. The market, on the other hand, rapidly bid up the price of new entrant Iliad SA (ILIAF.PK), as a result of forecasts for Iliad to capture significant mobile market share (which it did, around 10%). The wide divergence in price relative to changes in underlying value favor going long the incumbents, including Orange. Because this time it's different.

Top Telecom Companies To Watch For 2014: KDDI Corp (KDDIF)

KDDI CORPORATION is a telecommunications company. The Mobile Telecommunication segment is engaged in the provision of mobile communications services, including voice and data services, and mobile WIMAX services, as well as the sale of mobile communication terminals and the provision of contents. The Fixed-line Telecommunication segment provides broadband services, including fiber to the home (FTTH) and cable television (TV) services, as well as domestic and overseas communication services, data center services and information and communication technology (ICT) solution services. The Others segment is involved in the operation of call centers and the development of research and advanced technology. On December 2, 2013, it transferred all shares of a wholly owned subsidiary, JAPAN CABLE NET LIMITED to another subsidiary. In December 2013, the Company acquired the entire share capital in Yugen Kaisha Cosmos. Advisors' Opinion:

[By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Japanese stocks opened sharply higher Monday, with the Nikkei Stock Average (JP:NIK) advancing 1.1% to 14,242.86 after falling 2.8% Friday, as end-of-the-week gains for U.S. shares and some earnings news helped lift the market. The Topix also saw solid gains, up 0.8% in early moves. Major advances included a 2.5% rise for Hitachi Ltd. (JP:6501) (HTHIF) , a 4.1% surge for Mitsubishi Motors Corp. (JP:7211) (MMTOF) , and a 2.6% improvement for KDDI Corp. (JP:9433) (KDDIF) after the Nikkei business daily said the telecom will report a 50% increase for operating profit in the fiscal first half compared to a year earlier. Sony Corp. (JP:6758) (SNE) added 2% after scoring a Credit Suisse upgrade to outperform. Shares of NTT DoCoMo Inc. (JP:9437) (NTDMF) traded 1.1% higher after posting above-forecast quarterly results Friday, while JFE Holdings Inc. (JP:5411) (JFEEF) fell 3.2% after the steel producer also reported earnings.

Top Telecom Companies To Watch For 2014: Intelsat SA (I)

Advisors' Opinion:

[By Rich Duprey]
Satellite services provider�Intelsat (NYSE: I ) announced yesterday its second-quarter dividend of $0.799 per share on its 5.75% Series A mandatory convertible junior non-voting preferred stock, which trades on the NYSE under the symbol I.PRA.
[By Rich Duprey]
Satellite services provider Intelsat (NYSE: I ) announced yesterday its third-quarter dividend of $0.71875 per share on its 5.75% Series A mandatory convertible junior non-voting preferred stock, which trades on the NYSE under the symbol I.PRA.

Top Telecom Companies To Watch For 2014: TechnoConcepts Inc (TCPS)

Advisors' Opinion:

[By Peter Graham]
Small cap tech stocks TechnoConcepts, Inc (OTCMKTS: TCPS), Unisource Corporation (OTCMKTS: USRC) and Strategic Global Investments, Inc (OTCMKTS: STBV) have been getting some attention lately in various investment newsletters thanks to promotions. Of course, there is nothing wrong with properly disclosed promotions, but they can backfire on the unwary as its really up to investors or traders alike to do their own due diligence before investing or trading. With that in mind, here is a quick reality check about three small cap tech stocks getting a bit of attention lately:
TechnoConcepts, Inc (OTCMKTS: TCPS) Has the Yield Sign Replaced on Its OTC Page
Small cap TechnoConcepts is a wireless technology company currently holding patents and other intellectual property. On Friday, TechnoConcepts fell 0.45% to $15.58 for a market cap of $415.28 million plus TCPC is up 1.1% over the past year and up 6% since April 2012 according to Google Finance.

Top Telecom Companies To Watch For 2014: Vivendi SA (VIVHY)

Vivendi SA (Vivendi), incorporated on December 18, 1987, is a communications and entertainment company. As of December 31, 2009, the Company had six business segments: Activision Blizzard, Universal Music Group, SFR, Maroc Telecom Group, GVT (Holding) S.A. (GVT) and Canal+ Group. Activision Blizzard develops, publishes and distributes interactive entertainment software, online or on other media (such as console and personal computer (PC)). Universal Music Group is engaged in the sale of recorded music (physical and digital media), exploitation of music publishing rights, as well as artist services and merchandising. SFR is engaged in the phone services (mobile, broadband Internet and fixed) in France. Maroc Telecom Group is a telecommunication operator (mobile, fixed and Internet) in Africa, principally in Morocco, as well as in Mauritania, Burkina Faso, Gabon and Mali. GVT is a Brazilian fixed and broadband operator. Canal+ Group is engaged in publishing and distribution of pay-television mainly in France, in both analog and digital (terrestrially, via satellite or ADSL), as well as film production in Europe. In July 2013, Vivendi SA and Universal Music Group announced the completion of the sale of Parlophone Label Group to Warner Music Group Corp.

On November 13, 2009, Vivendi acquired an aggregate of 29.9% of GVT�� outstanding voting shares from Swarth Investments LLC, Swarth Investments Holdings LLC and Global Village Telecom (Holland) BV. In addition, Vivendi acquired from third parties an additional 8% interest in GVT's outstanding shares. On December 28, 2009, Canal+ Group, Vivendi�� subsidiary, acquired TF1�� 9.9% interest in the capital of Canal+ France. On July 31, 2009, Maroc Telecom acquired 51% controlling interest in Sotelma. On August 27, 2009, CID, a company 40% owned by SFR and 60% by other financial investors, acquired the 62% interest in 5 sur 5.

Advisors' Opinion:

[By Demitrios Kalogeropoulos]
Activision Blizzard (NASDAQ: ATVI ) is striking out on its own. The company reached a purchase agreement with Vivendi (NASDAQOTH: VIVHY ) �to transfer enough shares so that it will become an independent company, one that's majority-owned by public investors rather than a single corporation.

Wednesday, November 12, 2014

Top Low Price Stocks To Own Right Now

With shares of Amazon (NASDAQ:AMZN) trading around $274, is AMZN an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Amazon serves consumers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. It offers programs that enable sellers to sell their products on its websites, their own branded websites, fulfill orders through them, and programs that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and relatively low prices offered. Amazon is a leader in the Internet commerce space so look for them to continue to see rising profits, as consumers and companies opt for this method of shopping and selling over the standard method.

T = Technicals on the Stock Chart are Strong

Top Low Price Stocks To Own Right Now: Imperial Oil Limited(IMO)

Imperial Oil Limited engages in the exploration, production, and sale of crude oil and natural gas in Canada. The company operates through three segments: Upstream, Downstream, and Chemical. The Upstream segment engages in the exploration and production of conventional crude oil, natural gas, synthetic oil, and bitumen primarily in the Western Provinces, the Canada Lands, and the Atlantic Offshore. Its primary conventional oil producing asset includes the Norman Wells oil field in the Northwest Territories. The Downstream segment engages in the transportation and refining of crude oil, as well as blending, distribution, and marketing of refined products. It owns and operates crude oil, and natural gas liquids and products pipelines in Alberta, Manitoba, and Ontario. The Chemical segment engages in the manufacture and marketing of various petrochemicals, including ethylene, benzene, aromatic and aliphatic solvents, plasticizer intermediates, and polyethylene resin. As of De cember 31, 2010, Imperial Oil Limited had 1,204 million oil-equivalent barrels of proved undeveloped reserves; maintained a nation-wide distribution system, including 24 primary terminals, to handle bulk and packaged petroleum products moving from refineries to market by pipeline, tanker, rail, and road transport; and sold petroleum products through 1,850 Esso retail service stations, of which approximately 510 were company owned or leased. The company was founded in 1880 and is headquartered in Calgary, Canada. Imperial Oil Limited operates as a subsidiary of Exxon Mobil Corporation.

Advisors' Opinion:

[By Ben Levisohn]
We downgrade ExxonMobil to Underweight from Equal Weight primarily due to its relative valuation. The shares are currently trading at a 9% premium to its NAV compared to the group average discount of 17%. Although we have modestly increased our price target to $105 from $100 and set it above its NAV estimate to give credit to the company�� seemingly conservative non-proved resource estimate, we believe the potential upside is limited compared to other names in our coverage. We think the stock will continue to face relative headwinds concerning the lack of meaningful near-term production growth and our belief of a relatively steady high oil price environment. We recommend switching from ExxonMobil to ConocoPhillips, Imperial Oil (IMO), or Suncor. That said, ExxonMobil will likely outperform the group in the event of any unexpected significant negative macro developments given its long held ��afe haven��status.
[By Vanin Aegea]
Two companies that have been around for some time now are Imperial Oil (IMO) and Pembina Pipeline (PBA). Political instability in the Middle East has also given an extra relevance to the reserves found at this region, so let us see what the future holds and what gurus think of them.
[By MONEYMORNING.COM]
Imperial Oil Ltd. (NYSEMKT: IMO) is a $44 billion, integrated Oil and Gas Company engaged in the exploration, production, and sale of crude oil and natural gas in Canada. The company operates through three segments: upstream, downstream, and chemical. The downstream segment is engaged in refining of crude oil and represents about 37% of firm's net income.
[By Stephan Dube]
Cold Lake's most notable producers:
Husky Energy (HUSK.PK), see article here.Pengrowth Energy Corporation (PGH), see article here.Southern Pacific Resource (STPJF.PK), see article here.Canadian Natural Resources (CNQ), see article here.Devon Energy (DVN), see article here.Imperial Oil (IMO), see article here.Baytex, see article here.Bonavista Energy (BNPUF.PK), see article here.
Athabasca's most notable producers:

Top Low Price Stocks To Own Right Now: TigerLogic Corporation(TIGR)

TigerLogic Corporation engages in the design, development, sale, and support of software infrastructure, Internet search enhancement tools, and a social media content aggregation platform in North America, the United Kingdom, France, and Germany. The company offers Yolink, a search enhancement technology; and TigerLogic XDMS, an enterprise native XML database management server with data and document centric capabilities. It also provides multi-dimensional databases consisting of D3 data base management system that runs on various operating systems and allows application programmers to create new business solution software; mvEnterprise and mvBase, the multi-dimensional database solutions; and TigerLogic dashboard, which allows Pick UDM developers to create Web-based graphical displays of multi-value data. In addition, the company offers rapid application development tools that support the full life cycle of software application development and are used for rapid prototypin g, development, and deployment of graphical user interface client/server and Web applications. Further, it provides Postano, a real-time social media content aggregation platform, which allows users to collect content from various social media sources and display that content on Web pages hosted by the company or others. Additionally, the company offers technical support, consulting, continuing maintenance, customer support, professional, and training services. It serves independent software vendors and software developers, and corporate information technology departments. TigerLogic Corporation sells its products through OEMs, system integrators, specialized vertical application software developers, and consulting organizations, as well as directly to end user organizations and through its Web sites. The company was formerly known as Raining Data Corporation and changed its name to TigerLogic Corporation in April 2008. TigerLogic Corporation was founded in 1987 and is based in Irvine, California.

Advisors' Opinion:

[By Monica Gerson]
TigerLogic (NASDAQ: TIGR) is estimated to post its Q4 earnings.

Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Hot Cheap Companies To Watch For 2015: Nathan's Famous Inc.(NATH)

Nathan's Famous, Inc. operates in the foodservice industry. It engages in marketing Nathan?s Famous brand, and selling products bearing the Nathan?s Famous trademarks through various channels of distribution in the United States and internationally. The company operates and franchises quick-service restaurant units that features Nathan?s beef hot dogs, crinkle-cut french-fries, and other menu offerings under the Nathan?s Famous brand name. It also provides licensing agreements for the sale of Nathan?s products within supermarkets, club stores, and other grocery-type outlets; and involves in the manufacture of spices, and sale of Nathan?s products directly to other foodservice operators. In addition, the company offers Arthur Treacher?s brand fish fillets. As of August 3, 2011, its restaurant system consisted of 269 Nathan?s units, including 264 franchised units and 5 company-owned units (including 1 seasonal unit). The company was founded in 1916 and is based in Je richo, New York.

Advisors' Opinion:

[By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Nathan's Famous (Nasdaq: NATH ) , whose recent revenue and earnings are plotted below.
[By Chris Hill]
In this installment of Investor Beat, our analysts explain why they're watching Nathan's Famous (NASDAQ: NATH ) and Sony (NYSE: SNE ) .

Top Low Price Stocks To Own Right Now: Saks Incorporated(SKS)

Saks Incorporated operates retail stores in the United States. Its stores offer an assortment of fashion apparel, shoes, accessories, jewelry, cosmetics, and gifts. The company operates stores under the brand name of Saks Fifth Avenue (SFA) that are principally free-standing stores in shopping destinations or anchor stores in upscale regional malls. It also operates Saks Fifth Avenue OFF 5TH (OFF 5TH) stores, which are primarily located in upscale mixed-use and off-price centers. As of January 28, 2012, the company operated 46 SFA stores; and 60 OFF 5TH stores. Saks Incorporated also sells its products online at saks.com, as well as through catalogs. The company was founded in 1919 and is headquartered in New York, New York.

Advisors' Opinion:

[By Paul Ausick]
The only earnings reports of note since last Friday came from Saks Inc. (NYSE: SKS) which is trading down 0.2% at $15.99.

Before markets open Tuesday morning we are scheduled to hear results from Perfect World Co. Ltd. (NASDAQ: PWRD), Urban Outfitters Inc. (NASDAQ: URBN), Barnes & Noble Inc. (NYSE: BKS) which announced a new video app today, Best Buy Co. Inc (NYSE: BBY) which is included in our preview of this week�� results from retailers, Dick�� Sporting Goods Inc. (NYSE: DKS), Home Depot Inc. (NYSE: HD), J.C. Penney Co. Inc. (NYSE: JCP), and Trina Solar Ltd. (NYSE: TSL).
[By Holly LaFon]
During the year we made a number of portfolio changes. In addition to Forest Oil Corp., positions in Carters, Inc., John Wiley & Sons, Inc., Class A shares, and General Communication, Inc., Class A shares were eliminated and Saks, Inc. (SKS) was sold due to the company's acquisition by Hudson's Bay Company (TSX:HBC) (the $16 takeover price compared to our cost of approximately $4 .25 per share). One new position, Radian Group, Inc. (RDN), was established. One of the largest private mortgage insurance companies, Radian Group, Inc. should benefit from a recovery in the housing industry and from the Federal Housing Administration's gradual pull-back from the mortgage insurance market.
[By Andrew Marder]
The 1% has seen phenomenal income growth recently, and that's spurred growth at companies like Saks (NYSE: SKS ) and Nordstom (NYSE: JWN ) , both of which managed 5% increases in revenue in the last quarter.
[By Rich Duprey]
The own of upscale retailer Lord & Taylor is adding another luxury nameplate to its portfolio. Canadian shop Hudson's Bay will buy Saks (NYSE: SKS ) , the two retailers jointly announced, in a deal valued at about $2.9 billion, including debt.

Top Low Price Stocks To Own Right Now: Investors Title Company(ITIC)

Investors Title Company, through its subsidiaries, provides title insurance to residential, institutional, commercial, and industrial properties. It underwrites land title insurance for owners and mortgagees as a primary insurer; and offers the reinsurance of title insurance risks to other title insurance companies. The company also provides tax-deferred real property exchange services, as well as serves as an exchange accommodation titleholder and holds property for exchangers in reverse exchange transactions; offers investment management and trust services to individuals, companies, banks, and trusts; and provides consulting services to title insurance agencies. Investors Title Company serves various customers in the residential and commercial market sectors of the real estate industry. It issues title insurance policies primarily through approved attorneys from underwriting offices, as well as through independent issuing agents in 24 states and the District of Columbia, the United States. The company was founded in 1972 and is headquartered in Chapel Hill, North Carolina.

Advisors' Opinion:

[By CRWE]
Investors Title Company (NASDAQ:ITIC), reported its results for the second quarter ended June 30, 2012. Net income increased 110.0% to $3,349,488, or $1.57 per diluted share, compared with $1,594,805, or $0.74 per diluted share, for the prior year quarter.

Top Low Price Stocks To Own Right Now: Revive Therapeutics Ltd (RVV)

Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. The Company is also developing a next generation analog of REV-001, which is an improvement of the original compound and it will have the potential to treat new diseases that would otherwise remain untreated with the original compound, such as rare diseases, breathing disorders, and cognitive dysfunction. Advisors' Opinion:

[By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.